newsfilter
← Latest News
GlobeNewswire·

Axovant Completes Enrollment of Low-Dose Cohort in Phase 1/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I (Infantile Onset) Patients with GM1 Gangliosidosis

- Six-month data from low-dose cohort expected in Q4 2020- IND amended to include Type I (infantile onset) patients and to evaluate a higher dose- Expect to initiate high-dose cohort in 2H 2020 ...